[China Sunergy Announces Third Quarter 2011 Financial Results Reports Net Loss but Highest Quarterly Shipments to Date and Strong Cash Position NANJING, China, November 17, 2011 - China Sunergy Co., Ltd. (NASDAQ: CSUN) (“China Sunergy” or “the Company”), a specialized solar cell and module manufacturer, today announced its financial results for the third quarter ended September 30, 2011. The results]
[Form 6-K TABLE OF CONTENTS Page 3 4]
[China Sunergy Announces Third Quarter 2011 Financial Results Reports Net Loss but Highest Quarterly Shipments to Date and Strong Cash Position NANJING, China, November 17, 2011 - China Sunergy Co., Ltd. (NASDAQ: CSUN) (“China Sunergy” or “the Company”), a specialized solar cell and module manufacturer, today announced its financial results for the third quarter ended September 30, 2011. The results]
[Form 6-K TABLE OF CONTENTS Page 3 4]
[rd YEAR 2011 / 3 RESULTS OF OPERATIONS OF GLOBAL SOURCES LTD. The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying financial statements. Overview We are a leading business-to-business (B2B) media company and a primary facilitator of two-way trade with Greater China. The core business is facilitating trade from Greater] [GLOBAL SOURCES LTD. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In U.S. Dollars Thousands, Except Number of Shares and Per Share Data) As at September 30, As at December 31, 2011 2010 (Unaudited) ASSETS Current assets Cash and cash equivalents $ 77,110 $ 101,298 Term deposits with banks 1,786 1,411 Financial assets, available-for-sale] [GLOBAL SOURCES LTD. AND SUBSIDIARIES ACTUAL GAAP TO IFRS RECONCILIATION (In U.S. Dollars Thousands) Three months Nine months ended September 30, ended September 30, 2010 2010 U.S. GAAP Net Income Attributable to the Company $ 2,282 $ 12,121 IFRS conversion adjustments:]
[TPI Reports First Quarter Fiscal Year 2012 Financial Results CHENGDU, China, Nov. 14, 2011 Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (TCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the first quarter of Fiscal Year 2012. First quarter fiscal year 2012 ending September 30, 2011] [Tianyin Pharmaceutical, Incorporated First Quarter 2012 Annual Financial Results Conference Call November 14, 2011 Operator: Dr. James Tong: 1 Sales for the quarter ended September 30, 2011 was $17.5 million, a decrease of 20.5% as compared to $22 million for the quarter ended September 30th, 2010. The sales decrease was mainly due to the pricing pressure on our generic pharmaceuticals,] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT November 14, 2011 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. 000-52236 Delaware of incorporation) Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o o Item 7.01. Regulation FD Disclosure Description]
